Neuron23™ Inc. today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO).
Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer Read More »
Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician’s choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET) -mutant medullary thyroid cancer (MTC).
Genprex, Inc. today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs.
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs Read More »
Medtronic plc announced financial results for its first quarter of fiscal year 2024, which ended July 28, 2023.
Medtronic reports first quarter fiscal 2024 financial results Read More »
BerGenBio ASA announced that additional clinical data of bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small Cell Lung Cancer have been recently published and accepted for presentation at two upcoming international oncology conferences.
Genethon, a pioneer and leader in gene therapy research and development for rare genetic diseases, announced positive Phase 1/2 clinical trial results of its gene therapy, GNT-0003, for Crigler-Najjar syndrome were published in The New England Journal of Medicine.
Shoulder Innovations Inc., a Grand Rapids, Michigan-based leader in the shoulder replacement implant market, announced securing of a $45M debt facility in partnership with Trinity Capital.
Shoulder Innovations Announces Securing of a $45M Debt Facility Read More »
Kintor Pharmaceutical Limited announced that the company has completed the enrollment of 180 patients for the Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera compound GT20029 in China for the treatment of male androgenetic alopecia.
Berlin Heals Holding AG, a Swiss medical technology company, is delighted to announce the appointments of Dr. Felix Baader and Roland Diggelmann as new members of the Board of Directors.
PureTech Health plc plans to announce its half-yearly results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.
